Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics

被引:8
|
作者
Yuan, Heng [1 ]
Jung, Eun-Soo [2 ,3 ,4 ]
Chae, Soo-Wan [2 ,3 ,4 ]
Jung, Su-Jin [2 ,3 ,4 ]
Daily, James W. [5 ]
Park, Sunmin [1 ,6 ]
机构
[1] Hoseo Univ, Dept Bioconvergence, Asan 31499, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[3] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[4] Jeonbuk Natl Univ, Res Inst Clin Med, Jeonju 54907, South Korea
[5] Daily Mfg Inc, Dept R&D, Rockwell, NC 28138 USA
[6] Hoseo Univ, Obes Diabet Res Ctr, Dept Food & Nutr, 20 Hoseoro79 Bungil, Asan 31499, South Korea
关键词
metabolic dysfunction-associated steatotic liver disease; HFFs; gut microbiota; omics approach; HEPATIC STEATOSIS; NONCODING RNAS; DISEASE; PATHOGENESIS; CELLS; INFLAMMATION; CROSSTALK; NAFLD; NASH;
D O I
10.3390/nu16183061
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Metabolic dysfunction-associated steatotic liver disorder (MASLD) is increasingly prevalent globally, highlighting the need for preventive strategies and early interventions. This comprehensive review explores the potential of health functional foods (HFFs) to maintain healthy liver function and prevent MASLD through an integrative analysis of network pharmacology, gut microbiota, and multi-omics approaches. We first examined the biomarkers associated with MASLD, emphasizing the complex interplay of genetic, environmental, and lifestyle factors. We then applied network pharmacology to identify food components with potential beneficial effects on liver health and metabolic function, elucidating their action mechanisms. This review identifies and evaluates strategies for halting or reversing the development of steatotic liver disease in the early stages, as well as biomarkers that can evaluate the success or failure of such strategies. The crucial role of the gut microbiota and its metabolites for MASLD prevention and metabolic homeostasis is discussed. We also cover state-of-the-art omics approaches, including transcriptomics, metabolomics, and integrated multi-omics analyses, in research on preventing MASLD. These advanced technologies provide deeper insights into physiological mechanisms and potential biomarkers for HFF development. The review concludes by proposing an integrated approach for developing HFFs targeting MASLD prevention, considering the Korean regulatory framework. We outline future research directions that bridge the gap between basic science and practical applications in health functional food development. This narrative review provides a foundation for researchers and food industry professionals interested in developing HFFs to support liver health. Emphasis is placed on maintaining metabolic balance and focusing on prevention and early-stage intervention strategies.
引用
收藏
页数:22
相关论文
共 50 条
  • [41] Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials
    Wu, Juan
    Chen, Xiaoyang
    Qian, Jun
    Li, Guochun
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [42] Fermented rhubarb alleviates metabolic dysfunction-associated steatotic liver disease symptoms by modulating gut microbiota and activating the hepatic insulin signaling pathway
    Yuan, Heng
    Zhou, Junyu
    Zhang, Ting
    Wu, Xuangao
    Li, Chen
    Yang, Hee-Jong
    Jeong, Do Yeon
    Park, Sunmin
    FOOD BIOSCIENCE, 2025, 63
  • [43] Epidemiological Study on the Interaction between the PNPLA3 (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Sato, Satoshi
    Iino, Chikara
    Sasada, Takafumi
    Soma, Go
    Furusawa, Keisuke
    Yoshida, Kenta
    Sawada, Kaori
    Mikami, Tatsuya
    Nakaji, Shigeyuki
    Sakuraba, Hirotake
    Fukuda, Shinsaku
    GENES, 2024, 15 (09)
  • [44] Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial
    Jin, Yufeng
    Wang, Xin
    Chen, Ke
    Chen, Yu
    Zhou, Lixin
    Zeng, Yupeng
    Zhou, Yuqing
    Pan, Zhijun
    Wang, Di
    Li, Zhongxia
    Liang, Yongqian
    Ling, Wenhua
    Li, Dan
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [45] Temporal Trends and Regional Disparities in the Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) From 1980 to 2021: An Analysis of GBD Study 2021
    Anwar, Muhammad Tayyab
    Shahzil, Muhammad
    Maryyam, Liaqat
    Rehman, Wania
    Shaukat, Muhammad Talha
    Siddiqui, Rija
    Shahzaib, Muhammad
    Rehman, Aqeeb Ur
    Mohsin, Aleenah
    Fazal, Muhammad Imtanan
    Amjad, Zunaira
    Mohsin, Ali
    Farooq, Sibgha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1434 - S1435
  • [46] Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy
    Guney-Coskun, Merve
    Basaranoglu, Metin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (43)
  • [47] Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis
    Wu, Xuanlin
    Pan, Tao
    Fang, Zhihao
    Hui, Titi
    Yu, Xiaoxiao
    Liu, Changxu
    Guo, Zihao
    Liu, Chang
    JOURNAL OF INFLAMMATION RESEARCH, 2025, 18 : 1639 - 1656
  • [48] ARTIFICIAL INTELLIGENCE (AI) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A DUAL APPROACH FOR INNOVATING GENOMIC ANALYSIS AND DEVELOPMENT OF RISK PREDICTION MODELS
    Longo, Miriam
    Paolini, Erika
    Meroni, Marica
    Alisi, Anna
    Soardo, Giorgio
    Fracanzani, Anna Ludovica
    Dongiovanni, Paola
    HEPATOLOGY, 2024, 80 : S634 - S634
  • [49] Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review
    Ku, Jie-Lun
    Hsu, Jia-Rou
    Li, Yung-Tsung
    Wu, Li-Ling
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (01) : 33 - 40
  • [50] Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
    Huang, Xiaoyan
    Wu, Miaohui
    Huang, Baoliang
    Zhang, Yi
    FRONTIERS IN MEDICINE, 2025, 12